Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Cut to $145.00 by Analysts at JPMorgan Chase & Co.

Posted by Stanley Muller on Oct 15th, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price target reduced by JPMorgan Chase & Co. from $146.00 to $145.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 62.97% from the stock’s current price.

A number of other research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Rhythm Pharmaceuticals in a report on Friday, August 28th. They issued a “hold” rating and a $120.00 target price for the company. Leerink Partners assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, September 14th. They set an “outperform” rating and a $133.00 price target on the stock. Royal Bank Of Canada upped their price target on shares of Rhythm Pharmaceuticals from $155.00 to $159.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, June 17th. Finally, Citizens Jmp lifted their price objective on shares of Rhythm Pharmaceuticals from $155.00 to $160.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 5th. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $142.50.

Check Out Our Latest Report on RYTM

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM traded up $2.27 during trading hours on Thursday, reaching $88.98. The stock had a trading volume of 129,617 shares, compared to its average volume of 758,112. Rhythm Pharmaceuticals has a 52 week low of $74.50 and a 52 week high of $122.20. The company has a 50 day moving average price of $102.83 and a two-hundred day moving average price of $97.88. The stock has a market capitalization of $6.10 billion, a PE ratio of -28.55 and a beta of 2.01.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.08. The business had revenue of $71.25 million for the quarter, compared to analysts’ expectations of $67.66 million. Rhythm Pharmaceuticals had a negative return on equity of 159.87% and a negative net margin of 85.59%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.75) EPS. Equities research analysts predict that Rhythm Pharmaceuticals will post -2.75 EPS for the current year.

Insider Activity

In other Rhythm Pharmaceuticals news, insider Alastair Garfield sold 7,763 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $117.57, for a total transaction of $912,695.91. Following the completion of the transaction, the insider directly owned 2,295 shares of the company’s stock, valued at $269,823.15. The trade was a 77.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter C. Smith sold 62,774 shares of Rhythm Pharmaceuticals stock in a transaction on Monday, August 31st. The stock was sold at an average price of $105.46, for a total transaction of $6,620,146.04. Following the transaction, the chief financial officer directly owned 114,024 shares of the company’s stock, valued at $12,024,971.04. The trade was a 35.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 258,450 shares of company stock worth $28,796,497. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Pictet Asset Management Holding SA raised its position in Rhythm Pharmaceuticals by 8.5% in the 1st quarter. Pictet Asset Management Holding SA now owns 667,046 shares of the company’s stock worth $57,329,000 after purchasing an additional 52,383 shares during the period. Orbimed Advisors LLC raised its holdings in shares of Rhythm Pharmaceuticals by 31.0% in the first quarter. Orbimed Advisors LLC now owns 314,100 shares of the company’s stock worth $27,317,000 after buying an additional 74,300 shares during the period. Nan Fung Group Holdings Ltd purchased a new stake in shares of Rhythm Pharmaceuticals in the second quarter worth approximately $5,453,794. Squarepoint Ops LLC lifted its stake in shares of Rhythm Pharmaceuticals by 60.8% during the 2nd quarter. Squarepoint Ops LLC now owns 422,921 shares of the company’s stock worth $46,957,000 after acquiring an additional 159,953 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter valued at $6,823,000.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

Positive Sentiment: Rhythm launched IMCIVREE (setmelanotide) commercially in Japan for patients with acquired hypothalamic obesity. The launch follows approval from Japan’s Ministry of Health, Labour and Welfare and inclusion on the National Health Insurance drug-price list. IMCIVREE is the first approved treatment in Japan for this condition, creating a potential new source of international revenue. Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE in Japan
Positive Sentiment: Zacks upgraded RYTM to a Rank #2 (Buy), citing improving optimism about the company’s earnings prospects. The upgrade may support near-term investor sentiment. Rhythm Pharmaceuticals Upgraded to Buy
Neutral Sentiment: HC Wainwright maintained a Buy rating and a $130 price target, well above the recent trading level. The firm raised its FY2026 EPS forecast to a loss of $2.28 from a loss of $2.96 and slightly improved its Q3 and Q4 2026 estimates, indicating expectations for better near-term results.
Negative Sentiment: HC Wainwright reduced several 2027 forecasts, including FY2027 EPS to a loss of $0.62 from projected earnings of $0.53. Estimates were also lowered for the second and third quarters of 2027 and Q4 2027, signaling that the path to profitability may be slower than previously expected.

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases of obesity and other disorders involving the melanocortin-4 receptor (MC4R) pathway. The company’s research is centered on conditions in which genetic defects disrupt the body’s regulation of appetite, hunger and energy expenditure.

Rhythm’s lead product is IMCIVREE (setmelanotide), an MC4R agonist designed to restore signaling in the brain’s melanocortin pathway.